Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer
Phase II Randomized Study of High-Dose Ketoconazole With or Without Alendronate Sodium in Patients With Androgen-Independent Metastastic Adenocarinoma of the Prostate
Sponsor: National Cancer Institute (NCI)
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from National Cancer Institute (NCI)
Other Adenocarcinoma of the Prostate trials with similar outcome
This PHASE2 trial investigates Adenocarcinoma of the Prostate and Bone Metastases and is currently terminated or withdrawn. National Cancer Institute (NCI) leads this study, which shows 6 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Apr 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Mar 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .